Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

Biotechnology

Education

Sonoma Biotherapeutics

Jeff Bluestone

Jimmy Chung

Stacey Delaney

Melisa S. Medrano

Taylor Le Donne

Michael Thomas

Claire Crowther

Katie Tuckwell

Sabrina Fox-Bosetti

Melita Dvorak-Ewell

Jessica Stitt

Peter Dilaura

Doug Sheehy

Fred Ramsdell

The executive team at Sonoma Biotherapeutics has a wealth of experience in the healthcare industry. They have worked as entrepreneurs, strategic advisors, and CEOs at various companies. They also have a strong academic background, with degrees from top universities in economics and business.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Sonoma Biotherapeutics

Leadership Team

Board of Directors